• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Fraser 健康肾脏计划血液透析患者钙化防御风险因素的特征-一项匹配病例对照回顾性研究。

Characterization of Risk Factors for Calciphylaxis in Hemodialysis Patients in the Fraser Health Renal Program - A Matched Case-Control Retrospective Review.

机构信息

Department of Pharmacy, Burnaby Hospital, Burnaby, BC, Canada.

Department of Pharmacy, Royal Columbian Hospital, New Westminster, BC, Canada.

出版信息

J Pharm Pract. 2023 Dec;36(6):1424-1437. doi: 10.1177/08971900221118444. Epub 2022 Aug 28.

DOI:10.1177/08971900221118444
PMID:36036088
Abstract

Calciphylaxis is a lethal and rare disease characterized by ischemic and necrotic skin lesions caused by vascular calcification of adipose tissue. There have been many risk factors analyzed in the literature; however, the pathogenesis of calciphylaxis is still not well understood and treatment options are limited due to the lack of interventional studies. Our objectives were to describe risk factors, prevalence, incidence, and outcomes for calciphylaxis in hemodialysis patients within the Fraser Health Renal Program. This was a retrospective matched case-control study of hemodialysis patients within the Fraser Health Renal Program. Hemodialysis patients with calciphylaxis were matched to hemodialysis patients without calciphylaxis in a 1:2 ratio for age and sex from September 2, 2017 to July 3, 2020. There was a total of 40 calciphylaxis cases matched to 80 controls. In the univariate analysis, peritoneal dialysis, higher body mass index, lower serum iron, lower transferrin saturation, sevelamer, cinacalcet, warfarin, iron (PO), and insulin were associated with increased risk of calciphylaxis. In the multivariate analysis, only peritoneal dialysis, serum iron, sevelamer, and warfarin were identified as significant and strong risk factors associated with calciphylaxis. A low prevalence of 1.9% and high mortality rate of 57.5% at 12 months was found for calciphylaxis cases. Significant risk factors associated with calciphylaxis were peritoneal dialysis, serum iron, sevelamer, and warfarin. Future studies should further investigate the impact of minimizing exposure to these risk factors to reduce calciphylaxis development.

摘要

钙化防御是一种罕见且致命的疾病,其特征为脂肪组织血管钙化导致的缺血性和坏死性皮肤损伤。文献中已经分析了许多风险因素;然而,由于缺乏干预性研究,钙化防御的发病机制仍未得到很好的理解,治疗选择也有限。我们的目的是描述弗雷泽健康肾脏计划中血液透析患者的钙化防御的风险因素、患病率、发病率和结局。这是弗雷泽健康肾脏计划中血液透析患者的回顾性匹配病例对照研究。2017 年 9 月 2 日至 2020 年 7 月 3 日,我们将钙化防御的血液透析患者与钙化防御的血液透析患者按年龄和性别 1:2 进行匹配。共有 40 例钙化防御病例与 80 例对照匹配。单因素分析显示,腹膜透析、较高的体重指数、较低的血清铁、较低的转铁蛋白饱和度、司维拉姆、西那卡塞、华法林、铁(PO)和胰岛素与钙化防御的风险增加相关。多因素分析显示,只有腹膜透析、血清铁、司维拉姆和华法林被确定为与钙化防御显著相关的强风险因素。钙化防御的患病率为 1.9%,12 个月的死亡率为 57.5%,这一结果表明钙化防御的患病率较低,死亡率较高。与钙化防御相关的显著风险因素包括腹膜透析、血清铁、司维拉姆和华法林。未来的研究应进一步探讨尽量减少接触这些风险因素以减少钙化防御发展的影响。

相似文献

1
Characterization of Risk Factors for Calciphylaxis in Hemodialysis Patients in the Fraser Health Renal Program - A Matched Case-Control Retrospective Review. Fraser 健康肾脏计划血液透析患者钙化防御风险因素的特征-一项匹配病例对照回顾性研究。
J Pharm Pract. 2023 Dec;36(6):1424-1437. doi: 10.1177/08971900221118444. Epub 2022 Aug 28.
2
A case-control study of calciphylaxis in Japanese end-stage renal disease patients.一例中日终末期肾病患者钙化防御的病例对照研究。
Nephrol Dial Transplant. 2012 Apr;27(4):1580-4. doi: 10.1093/ndt/gfr658. Epub 2011 Nov 25.
3
Risk factors for calciphylaxis in Chinese hemodialysis patients: a matched case-control study.中文版标题:中文版副标题:中文版作者名
Ren Fail. 2021 Dec;43(1):406-416. doi: 10.1080/0886022X.2021.1884094.
4
Calcium use increases risk of calciphylaxis: a case-control study.钙的使用增加了钙化防御的风险:一项病例对照研究。
Perit Dial Int. 1999 May-Jun;19(3):248-52.
5
Successful treatment of calciphylaxis by a multidisciplinary approach.采用多学科方法成功治疗钙过敏症。
BMJ Case Rep. 2014 Jul 17;2014:bcr2014204354. doi: 10.1136/bcr-2014-204354.
6
[Calciphylaxis: fatal complication of cardiometabolic syndrome in patients with end stage kidney disease].[钙过敏:终末期肾病患者心脏代谢综合征的致命并发症]
Nefrologia. 2008;28(1):32-6.
7
Successful Treatment of Calciphylaxis in a Young Female With End-Stage Renal Disease on Peritoneal Dialysis With Parathyroidectomy, Intensification of Dialysis, and Sodium Thiosulphate-A Case Report and Literature Review.甲状旁腺癌相关钙化防御的治疗:甲状旁腺切除术、强化透析和硫代硫酸钠治疗腹膜透析终末期肾病年轻女性 1 例报告及文献复习
J Investig Med High Impact Case Rep. 2021 Jan-Dec;9:23247096211060580. doi: 10.1177/23247096211060580.
8
Calciphylaxis after parathyroidectomy.甲状旁腺切除术后的钙化防御。
Hemodial Int. 2017 Oct;21 Suppl 2:S62-S66. doi: 10.1111/hdi.12599.
9
Calciphylaxis.钙过敏症
Curr Opin Nephrol Hypertens. 2017 Jul;26(4):276-281. doi: 10.1097/MNH.0000000000000328.
10
Distal calcific uremic arteriolopathy in a hemodialysis patient responds to lowering of Ca x P product and aggressive wound care.一名血液透析患者的远端钙化性尿毒症小动脉病对降低钙磷乘积及积极的伤口护理有反应。
Clin Nephrol. 2002 Sep;58(3):238-43. doi: 10.5414/cnp58238.

引用本文的文献

1
Interprovincial Differences in Access to Phosphate Lowering Medication; Implications for Care as Canada Moves Toward a National Pharmacare Program.获得降磷药物方面的省际差异;随着加拿大迈向全国性药物护理计划对医疗护理的影响。
Can J Kidney Health Dis. 2023 Nov 10;10:20543581231207467. doi: 10.1177/20543581231207467. eCollection 2023.
2
Multimodality approach to treat calciphylaxis in end-stage kidney disease patients.多模态方法治疗终末期肾病患者的钙化防御。
Ren Fail. 2023;45(2):2256413. doi: 10.1080/0886022X.2023.2256413. Epub 2023 Sep 19.